{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:47:48Z","timestamp":1787942868583,"version":"build-2784847793"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kyowa Kirin International plc"},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,1,2]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To report the impact of continued burosumab treatment on clinical laboratory tests of efficacy, patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia who continued from a 96-week phase 3 study into a 48-week open-label extension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible participants from the phase 3 study continued on the burosumab regimen received at the end of the phase 3 study for a further 48 weeks (n=31). Some (not all) received compassionate burosumab treatment between the two studies (a period of 6\u201318 months). The primary efficacy outcome was fasting serum phosphate concentration; secondary outcomes were serum 1,25 dihydroxyvitamin D concentration, renal phosphate reabsorption, PROs and ambulatory function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Improvements in fasting serum phosphate, serum 1,25 dihydroxyvitamin D and renal phosphate reabsorption at 96 weeks were maintained through the 48-week extension. Improvements were also maintained in stiffness and physical function measured using the Western Ontario and McMaster Universities Osteoarthritis Index, pain and fatigue endpoints measuring using the Brief Pain Inventory short-form and Brief Pain Inventory, respectively, and in ambulatory function (6-Minute Walk Test).<\/jats:p>\n                  <jats:p>A post-hoc exploratory analysis exploring outcomes in participants who discontinued burosumab treatment between the studies (n=7) and those who received at least one dose (n=23) indicated that the benefits of burosumab on clinical laboratory tests of efficacy, PROs and ambulatory function may be lost when treatment is interrupted but recover over time when treatment is reinstated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Continued treatment with burosumab appears necessary for sustained clinical benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>Phase 3: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02526160\">NCT02526160<\/jats:ext-link>; open-label extension: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03920072\">NCT03920072<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002676","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:00:15Z","timestamp":1677582015000},"page":"e002676","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02526160","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03920072","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04308096","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4226","authenticated-orcid":false,"given":"Peter","family":"Kamenicky","sequence":"first","affiliation":[{"name":"Service d'Endocrinologie et des Maladies de la Reproduction, H\u00f4pital Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-2601","authenticated-orcid":false,"given":"Karine","family":"Briot","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"F.I.R.M.O. Foundation, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"INSERM U1132 BIOSCAR, Service de Rhumatologie, H\u00f4pital Lariboisiere, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-4117","authenticated-orcid":false,"given":"Rachel K","family":"Crowley","sequence":"additional","affiliation":[{"name":"Rare Disease Clinical Trial Network, University College Dublin School of Medicine, Dublin, Ireland"},{"name":"Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disease Unit, Royal National Orthopaedic Hospital, Stanmore, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Kolta","sequence":"additional","affiliation":[{"name":"INSERM U1153, Service de Rhumatologie, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-2581","authenticated-orcid":false,"given":"Robin H","family":"Lachmann","sequence":"additional","affiliation":[{"name":"Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Lecoq","sequence":"additional","affiliation":[{"name":"Physiologie et Physiopathologie Endocriniennes, Assistance Publique - H\u00f4pitaux de Paris, Paris, France"},{"name":"Service d\u2019Endocrinologie et des Maladies de la Reproduction, H\u00f4pital Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-7586","authenticated-orcid":false,"given":"Stuart H","family":"Ralston","sequence":"additional","affiliation":[{"name":"Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J","family":"Rylands","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Department, Kyowa Kirin International PLC, Marlow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Department, Kyowa Kirin International PLC, Marlow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Kyowa Kirin Pharmaceutical Development, Inc, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-9491","authenticated-orcid":false,"given":"Annabel","family":"Nixon","sequence":"additional","affiliation":[{"name":"Chilli Consultancy, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nixon","sequence":"additional","affiliation":[{"name":"Chilli Consultancy, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0048","authenticated-orcid":false,"given":"Muhammad K","family":"Javaid","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"2025090312140128000_9.1.e002676.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1014-8","article-title":"Fgf23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025090312140128000_9.1.e002676.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-21784-1","article-title":"Exploring the link between serum phosphate levels and low muscle strength, dynapenia, and sarcopenia","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"2025090312140128000_9.1.e002676.3","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00198-022-06318-w","article-title":"Physical function and physical activity in adults with X-linked hypophosphatemia","volume":"33","author":"Orlando","year":"2022","journal-title":"Osteoporos Int"},{"key":"2025090312140128000_9.1.e002676.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1336"},{"key":"2025090312140128000_9.1.e002676.5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340"},{"key":"2025090312140128000_9.1.e002676.6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0661"},{"key":"2025090312140128000_9.1.e002676.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-018-0147-6"},{"key":"2025090312140128000_9.1.e002676.8","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090312140128000_9.1.e002676.9","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study","volume":"29","author":"Lo","year":"2020","journal-title":"Qual Life Res"},{"key":"2025090312140128000_9.1.e002676.10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025090312140128000_9.1.e002676.11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2018.01.013","article-title":"Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC\u00ae as clinical trial end points","volume":"21","author":"Theodore-Oklota","year":"2018","journal-title":"Value Health"},{"key":"2025090312140128000_9.1.e002676.12","doi-asserted-by":"publisher","DOI":"10.1038\/S41581-019-0152-5"},{"key":"2025090312140128000_9.1.e002676.13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025090312140128000_9.1.e002676.14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2025090312140128000_9.1.e002676.15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked Hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"key":"2025090312140128000_9.1.e002676.16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2025090312140128000_9.1.e002676.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.03.002"},{"key":"2025090312140128000_9.1.e002676.18","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200409000-00005"},{"key":"2025090312140128000_9.1.e002676.19","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N"},{"key":"2025090312140128000_9.1.e002676.20","article-title":"PRO152 confirmatory psychometric validation of the western ontario mcmaster universities osteoarthritis inventory (WOMAC) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar","year":"2019","journal-title":"Value Health"},{"key":"2025090312140128000_9.1.e002676.21","article-title":"PRO154 confirmatory psychometric validation of the brief pain inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar","year":"2019","journal-title":"Value Health"},{"key":"2025090312140128000_9.1.e002676.22","doi-asserted-by":"crossref","unstructured":"Nixon A , Williams A , Theodore-Oklota C . Psychometric validation of the brief fatigue inventory (BFI) inadult x-linked hypophosphatemia (XLH). Orlando, IN, USA: ISPOR, 2020.","DOI":"10.1016\/j.jval.2020.04.1301"},{"key":"2025090312140128000_9.1.e002676.23","unstructured":"ATS . ATS statement: guidelines for the six-minute walk test 2002. n.d. Available: https:\/\/www.thoracic.org\/statements\/resources\/pfet\/sixminute.pdf"},{"key":"2025090312140128000_9.1.e002676.24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090312140128000_9.1.e002676.25","doi-asserted-by":"crossref","first-page":"20406223221117470","DOI":"10.1177\/20406223221117471","article-title":"Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description","volume":"13","author":"Brandi","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"2025090312140128000_9.1.e002676.26","unstructured":"Brandi M , Liu J , Williams A , et al . First interim analysis of the international X-linked hypophosphataemia (XLH) registry: adult population baseline characteristics (abstract OP4-P280). World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, 2022."}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:14:09Z","timestamp":1756926849000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/rmdopen-2022-002676"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002676","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}